Searchable abstracts of presentations at key conferences in endocrinology

ea0041oc13.2 | Pituitary Clinical | ECE2016

Growth hormone and insulin signalling after acute GH exposure in patients with controlled acromegaly: impact of surgery versus somatostatin analog treatment

Dal Jakob , Lundby Hoyer Katrine , Pedersen Steen B , Magnusson Nils , Bjerrring Peter , Frystyk Jan , Moller Niels , Jessen Niels , Jorgensen Jens Otto L

Background: Somatostatin analogue treatment (SA) is used in acromegaly to suppress GH secretion and tumour growth. In addition, SA also suppresses insulin secretion and may impact on GH signalling in peripheral tissues.Objective: To compare GH and insulin signalling in skeletal muscle and adipose tissue in vivo before and after a single exogenous GH bolus in patients with acromegaly controlled by either surgery alone or by ongoing treatment with a slow-r...

ea0063gp136 | Obesity | ECE2019

Administration of a growth hormone bolus down-regulates gene-expression of the g0/g1 switch gene 2 (g0s2) in subcutaneous adipose tissue in healthy, obese men: a randomized, placebo-controlled, cross-over study

Hjelholt Astrid , Jessen Niels , Arlien-Soborg Mai Christiansen , Pedersen Steen Bonlokke , Jorgensen Jenso Otto Lunde

Background: Growth hormone (GH) potently stimulates lipolysis, and after GH exposure, levels of serum free fatty acids (FFAs) increase in a distinct temporal pattern characterized by a 1-hour lag phase and a peak after 3 hours followed by a gradual return to baseline. This effect predominantly operates during fasting and promotes utilization of lipids from adipose tissue (AT) at the expense of glucose and protein. Prolonged fasting also downregulates the expression of the G0/G...

ea0049ep654 | Obesity | ECE2017

Growth hormone signaling and action in obese versus lean human subjects: evidence of increased hepatic GH sensitivity in obesity

Pedersen Morten Hogild , Bak Ann Mosegaard , Pedersen Steen Bonlokke , Jessen Niels , Moller Niels , Jorgensen Jens O.L.

Context: Obesity is accompanied by blunted GH secretion but relatively normal serum IGF-I levels, which suggests increased GH sensitivity. This, however, remains to be tested at the level of GH signaling in human subjects.Objective: To compare the effects of an acute intravenous GH bolus in obese vs normal weight subjects on GH signaling pathways in adipose and muscle tissue, substrate metabolism and insulin sensitivity.Subjects an...

ea0035p671 | Growth hormone IGF axis basic | ECE2014

Epigenetic regulation of GH target genes and its relation to in vivo GH signaling in skeletal muscle of adult human males: a pilot study

Pedersen Morten H , Vestergaard Poul F , Switnicki Michal , Jessen Niels , Jorgensen Jens O L

Background: GH secretion and action change with age in adult human subjects, and this play an important role in substrate metabolism in aging subjects. Targeted disruption of the GH receptor in mice extends longevity, and this is associated with decreased expression of apoptosis-related genes including caspase-9 (CASP9) in skeletal muscle.Aim: To study DNA methylation of putative GH target genes in skeletal muscle of adult male subjects in relation to bo...

ea0022p508 | Growth factors | ECE2010

Insulin resistance induced by GH is transient and reversible: glucose clamp studies during different ambient GH levels in GH-deficient adults

Krusenstjerna-Hafstrom Thomas , Moller Niels , Christiansen Jens Sandahl , Jessen Niels , Jorgensen Jens Otto Lunde

Background: The impact of GH on insulin sensitivity is ambiguous since both long standing GH-deficiency as well as acute GH exposure and prolonged GH-excess are associated with insulin resistance.Aim: To test the hypotheses that the insulin antagonistic effect of GH i) is dynamic and depend on ambient GH levels and ii) subsides gradually with time after GH exposure.Methods: Eight GHDA participated in a randomised crossover study. E...

ea0056gp190 | Pituitary / Growth Hormone ' IGF Axis | ECE2018

Insulin sensitivity improves after disease control in acromegaly irrespective of treatment modality and despite an increase in intrahepatic lipid content: data from an investigator-initiated prospective trial

Arlien-Soborg Mai C , Dal Jakob , Madsen Michael , Hogild Morten , Jessen Niels , Jorgensen Jens Otto Lunde

Background: Active acromegaly induces insulin resistance despite a lean phenotype, both of which reverse by curative surgery. The impact of somatostatin analogue treatment on insulin sensitivity is less certain and may be offset by its anti-lipogenic effects.Aim: To study insulin sensitivity, body composition and extopic lipid content in newly diagnosed patients with acromegaly before and ≥6 months after successful surgical or medical treatment.</p...

ea0090p684 | Pituitary and Neuroendocrinology | ECE2023

Fibroblast Activation Protein in Patients with Growth Hormone Deficiency and Acromegaly: Before and After Treatment

Baek Amanda , Arlien-Soborg Mai C. , Kathrine Nissen Pedersen Anne , Jessen Niels , Bjerre Mette , Otto Lunde Jorgensen Jens

Background: It is well-known that growth hormone (GH) potently stimulates collagen turnover and it is associated with fibrosis in several tissues, but the mechanisms involved in GH-stimulated fibrosis are poorly elucidated. Fibroblast activation protein-α (FAPα) is an enzyme that can cleave collagens and is expressed almost only under pathological conditions such as fibrosis. FAPα also cleaves and inactivates fibroblast growth factor 21 (FGF21), which is a circu...

ea0063oc3.4 | Cushing's and acromegaly | ECE2019

Restoration of basal glucose turnover after disease control in acromegaly depends on treatment modality: a prospective, investigator-initiated trial

Arlien-Soborg Mai C , Dal Jakob , Madsen Michael , Hogild Morten , Hjelholt Astrid , Jessen Niels , Moller Niels , Otto Lunde Jorgensen Jens

Background: Growth Hormone (GH) reversibly suppresses insulin-stimulated glucose uptake in skeletal muscle, but less is known about GH effects on glucose metabolism in the basal state. Somatostatin suppresses GH as well as insulin, and may also exert direct effects in skeletal muscle. This may have therapeutic implications in the treatment of acromegalic patients with a somatostatin analogue (SA).Aim: To study basal and insulin-stimulated glucose metabol...

ea0063p209 | Diabetes, Obesity and Metabolism 1 | ECE2019

Insulin sensitivity and counter regulatory responses following hypoglycemia in healthy and type 1 diabetes patients

Bengtsen Mads Bisgaard , Stoy Julie , Rittig Nikolaj Fibiger , Voss Thomas Schmidt , Svart Mads Vandsted , Jessen Niels , Moller Niels

Background and aim: Insulin resistance is associated with type 2 diabetes and obesity but recent studies suggest that it may also be associated with type 1 diabetes (T1D), which may affect glycemic control. Hypoglycemia is a dreaded condition among patients with T1D and may also limit optimal glycemic management. We aimed to investigate insulin sensitivity and metabolic adaptions in healthy control subjects and T1D subjects.Material and methods: <!--SUB:...

ea0032p213 | Clinical case reports – Pituitary/Adrenal | ECE2013

Case report: chronic adrenergic stimulation induces brown adipose tissue differentiation in visceral adipose tissue

Sondergaard Esben , Gormsen Lars C , Pedersen Steen B , Christiansen Peer , Nielsen Soren , Poulsen Per L , Jessen Niels

Introduction: The presence of brown adipose tissue (BAT) in humans has recently been demonstrated by histology and positron emission tomography (PET). In previous reports, BAT in adults is primarily confined to the upper chest and neck. Here, we report a case of massive BAT infiltration of the visceral adipose tissue in a patient with catecholamine secreting paraganglioma.Methods: The patient was evaluated with [18F]-FDG PET/CT at three occasi...